Original articleVaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate
References (24)
Immunisation against bacterial meningitis
J Infect
(1981)- et al.
Characterization of Neisseria meningitidis capsular polysaccharides by pyrolysis mass spectrometry
Anal Biochem
(1980) - et al.
Prospects for the prevention of bacterial meningitis with polysaccharide vaccines
Bull WHO
(1978) - et al.
Human immunity to the meningococcus. I. The role of humoral antibodies
J Exp Med
(1969) - et al.
Human immunity to the meningococcus. II. Development of natural immunity
J Exp Med
(1969) The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man
J Exp Med
(1970)- et al.
The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia
J Infect Dis
(1977) - et al.
Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 month to 5 years of age in Finland
Pediatrics
(1977) - et al.
Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharide at the cellular level
J Immunol
(1969) - et al.
Characterization of the antibody response to type III pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response
Immunology
(1971)
Role of T-lymphocytes in the humoral immune response. I. Proliferation of B lymphocytes in thymus-deprived mice
J Immunol
Secondary IgG response to type III pneumococcal polysaccharide. III. T-cell requirement for development of B memory cells
Eur J Immunol
Cited by (9)
Replacing antibodies with modified DNA aptamers in vaccine potency assays
2017, VaccineCitation Excerpt :To explore the feasibility of using aptamers in a vaccine potency assay, we chose a polysaccharide vaccine conjugated to the protein carrier CRM197. CRM197 is a non-toxic form of diphtheria toxin used in many vaccines to improve the immunogenicity of a conjugated antigen such as a polysaccharide [14,15]. CRM197 is currently used in approved conjugate vaccines against meningitis, pneumococcus and Haemophilus influenza B [16,17] to improve immunogenicity.
Overview of the development and current use of CRM<inf>197</inf> conjugate vaccines for pediatric use
2010, VaccineCitation Excerpt :Glycoconjugate vaccines are made by coupling the polysaccharide capsule portion of the organism to a carrier protein. This combination is more immunogenic than the saccharide alone and is also capable of inducing T-cell memory booster responses upon revaccination [2]. Conjugate vaccines have been developed using several protein carriers, one of which is CRM197.
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
2022, Infectious Diseases and TherapyWhy might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium
2016, Globalization and HealthThe impact of protein-conjugate polysaccharide vaccines: An endgame for meningitis?
2013, Philosophical Transactions of the Royal Society B: Biological Sciences
- *
Present address: Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis, P.O. Box 9190, 1006 AD Amsterdam, The Netherlands.